美国食品和药物管理局批准杜普森特治疗青少年和成年人抗组胺药物失效的严重慢性疹. FDA approves Dupixent for severe chronic hives in teens and adults failing antihistamines.

美国食品和药物管理局批准Dupixent (dupilumab) 用于治疗12岁及以上患者的慢性自发性疹,这些患者对标准抗组胺药物治疗反应不佳. The FDA has approved Dupixent (dupilumab) for treating chronic spontaneous urticaria (CSU) in patients aged 12 and older who do not respond well to standard antihistamine treatments. 这是十多年来对CSU的首次新治疗。 This is the first new treatment for CSU in over a decade. 通过向特定的炎症途径,Dupixent有效地减少和疹等症状. Dupixent effectively reduces symptoms like itching and hives by targeting specific inflammatory pathways. 美国大约有300,000人有CSU 并没有得到目前治疗的有效控制。 About 300,000 people in the U.S. have CSU that is not well controlled by current treatments.